This month, Maryland’s Attorney General Brian Frosh petitioned the Supreme Court to uphold the “first-in-the-nation” law against drug price-gouging.
This month, Maryland’s Attorney General Brian Frosh petitioned the Supreme Court to uphold the “first-in-the-nation” law against drug price-gouging.The law gives the attorney general the authority to review price information about generic drugs. If the state’s lawyers could show that prices were increasing too steeply, they could seek to order the prices reduced, or issue fines to the drug companies.
The Association for Accessible Medicines (AAM) filed a suit against the state in a US district court in Maryland last year, alleging the bill grants the state “unprecedented powers to regulate the national pharmaceutical market, violating the [US] Constitution and posing harm to vulnerable patient communities.”
In April 2018, a federal appeals court in Maryland ruled that the law, which was passed in 2017, was unconstitutional. In explaining her decision to bar the law from taking effect, Judge Stephanie D. Thacker wrote an opinion stating that “Maryland cannot, even in an effort to protect its consumers from skyrocketing prescription drug costs, impose its preferences in this manner.”
After the decision in late April, Frosh requested that a full federal appeals court rehear the case, explaining that “The resolution of this appeal will substantially affect the responses of state governments to a problem with both fiscal and public health dimensions: the rapidly rising cost of prescription drugs.”
In July, a federal appeals court declined to hear a petition to rehear the case, letting the previous ruling stand.
In reaching the decision to decline to rehear the case, 9 judges voted against, 3 judges voted in favor, and 2 judges did not vote. One of the judges who voted in favor of rehearing the case before the full court, Judge James A. Wynn Jr., wrote that “At a minimum, [the case deserves] the careful deliberation of this entire Court.”
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed
July 15th 2024Sarfaraz K. Niazi, PhD, discusses the challenges with pharmacy benefit managers (PBMs) that plague the biosimilar industry and new legislation that attempts to reform their practices and encourage biosimilar adoption.